

Secondary Metabolites from the Male Cone of *Cycas vespertilio*

Vincent Antonio S. Ng¹, Esperanza Maribel G. Agoo², Chien-Chang Shen³, Consolacion Y. Ragasa^{1,4*}

¹Chemistry Department, De La Salle University 2401 Taft Avenue, Manila 1004, Philippines.

²Biology Department, De La Salle University 2401 Taft Avenue, Manila 1004, Philippines.

³National Research Institute of Chinese Medicine, 155-1, Li-Nong St., Sec. 2, Taipei 112, Taiwan.

⁴Chemistry Department, De La Salle University Science & Technology Complex Leandro V. Locsin Campus, Binan City, Laguna 4024, Philippines.

Available Online: 29th June, 2015

ABSTRACT

Chemical investigation of *Cycas vespertilio* male cone led to the isolation of pinoresinol (1), lariciresinol (2), mixtures of α -amyrin acetate (3a) and lupeol acetate (3b) in a 2.5:1 ratio and β -sitosterol (4a) and stigmasterol (4b) in a 2:1 ratio, triglycerides (5), and fatty alcohols (6). The structures of 1 and 2 were elucidated by extensive 1D and 2D NMR spectroscopy, while those of 3a-6 were identified by comparison of their ¹H and/or ¹³C NMR spectra with those reported in the literature.

Keywords: *Cycas vespertilio* male cone, Cycadaceae, pinoresinol, lariciresinol, α -amyrin acetate, lupeol acetate, β -sitosterol, stigmasterol, triglycerides, fatty alcohols

INTRODUCTION

Cycas, the only currently known genus of the Family Cycadaceae, are considered as fossil plants¹. Their long existence and persistence through time have sparked special interest in their biology and evolution. The cycads resemble palms in morphology, thus are commonly called sago palm. These are widely distributed in the Tropics, with species found in Asia, Africa, Southeast Asia, Pacific, and Australia². They also grow on volcanic, limestone, ultramafic, sandy, or even water-logged soils in grassland and forest habitats³. Of the eleven cycad species in the Philippines, ten are endemic to the country⁴. Except for our recent paper on the chemical constituents of *Cycas sancti-lasallei*⁵, there are no reported studies on the chemical constituents of these endemic cycad species.

This study is part of our research on the chemical constituents of *Cycas* species endemic to the Philippines. In an earlier study, we reported the isolation of squalene, β -sitosterol, stigmasterol, and triglycerides from the sarcotesta; β -sitosterol, stigmasterol, triglycerides and phytol fatty acid esters from the endotesta; β -sitosterol, stigmasterol, triglycerides, and β -sitosteryl fatty acid esters from the sclerotesta; and triglycerides and β -sitosteryl fatty acid esters from the bark of *Cycas sancti-lasallei*⁵. We report herein the isolation of pinoresinol (1), lariciresinol (2), triglycerides (5), and fatty alcohols (6) from the dichloromethane extract of *Cycas vespertilio* male cone. Mixtures of α -amyrin acetate (3a) and lupeol acetate (3b); and β -sitosterol (4a) and stigmasterol (4b) were also obtained from the dichloromethane extract.

MATERIALS AND METHODS

General experimental procedure

NMR spectra were recorded on a Varian VNMRs spectrometer in CDCl₃ at 600 MHz for ¹H NMR and 150 MHz for ¹³C NMR spectra. Column chromatography was performed with silica gel 60 (70-230 mesh). Thin layer chromatography was performed with plastic backed plates coated with silica gel F₂₅₄ and the plates were visualized by spraying with vanillin/H₂SO₄ solution followed by warming.

Plant material








Cycas vespertilio A. Lindstr. & K. D. Hill male cone were collected from Iloilo, Panay Island, Philippines in April 2013. Voucher specimens were collected and authenticated by one of the authors (EMGA) and deposited in the De La Salle University-Manila Herbarium (DLSUH 3112).

General isolation procedure

A glass column 18 inches in height and 1.0 inch internal diameter was used for the chromatography of the crude extracts. Twenty milliliter fractions were collected. All fractions were monitored by thin layer chromatography. Fractions with spots of the same *R_f* values were combined and rechromatographed in appropriate solvent systems until TLC pure isolates were obtained. A glass column 12 inches in height and 0.5 inch internal diameter was used for the rechromatography of smaller fractions from the first column. Five milliliter fractions were collected. Final purifications were conducted using Pasteur pipettes as columns. One milliliter fractions were collected.

Isolation of the chemical constituents of the male cone

*Author for Correspondence



5 R = R' = R'' = long chain fatty acids

The air-dried *C. vespertilio* male cone (85.0 g) was ground in a blender, soaked in CH_2Cl_2 for 3 days and then filtered. The solvent was evaporated under vacuum to afford a crude extract (0.8 g) which was chromatographed using

increasing proportions of acetone in CH_2Cl_2 at 10% increment. The 10% acetone in CH_2Cl_2 fraction was rechromatographed (3 \times) in 7.5% EtOAc in petroleum ether to yield **5** (5 mg). The 20% acetone in CH_2Cl_2 fraction

was rechromatographed in 5% EtOAc in petroleum ether. The less polar fractions were combined and rechromatographed (3 ×) in 5% EtOAc in petroleum ether to afford a mixture of **3a** and **3b** (4 mg) after washing with petroleum ether. The more polar fractions were combined and rechromatographed (2 ×) in 10% EtOAc in petroleum ether to afford **6** (4 mg) after washing with petroleum ether. The 40% acetone in CH₂Cl₂ fraction was rechromatographed in 20% EtOAc in petroleum ether to yield a mixture of **4a** and **4b** (5 mg) after washing with petroleum ether. The 80% acetone in CH₂Cl₂ fraction was rechromatographed (4 ×) in CH₃CN:Et₂O:CH₂Cl₂ (1:1:8 by volume) to yield **1** (9 mg) after trituration with petroleum ether. The acetone fraction was rechromatographed (5 ×) in CH₃CN:Et₂O:CH₂Cl₂ (2:2:6, v/v) to yield **2** (8 mg) after trituration with petroleum ether.

Pinoresinol (1): ¹³C NMR (150 MHz, CDCl₃): δ 85.86 (C-1), 54.15 (C-2), 71.66 (C-3), 132.90 (C-1'), 108.56 (C-2'), 146.68 (C-3'), 145.22 (C-4'), 114.24 (C-5'), 118.95 (C-6'), 55.94 (3'-OCH₃).

Lariciresinol (2): ¹³C NMR (150 MHz, CDCl₃): δ 82.81 (C-1), 52.61 (C-2), 42.41 (C-3), 72.90 (C-4), 33.35 (C-5), 60.96 (C-6), 134.77 (C-1'), 108.25 (C-2'), 146.61 (C-3'), 145.02 (C-4'), 114.14 (C-5'), 118.75 (C-6'), 132.27 (C-1''), 121.19 (C-2''), 146.49 (C-3''), 143.98 (C-4''), 114.38 (C-5''), 111.16 (C-6''), 55.93, 55.91 (2 × OCH₃).

α-Amyrin acetate (3a): ¹H NMR (600 MHz, CDCl₃): δ ¹H NMR d: 0.80 (6H, s), 0.83 (3H, s), 0.89 (6H, s), 0.90 (3H, s), 0.99 (3H, s), 1.00 (3H, s), 2.03 (3H, s), 4.49 (1H, m, H-3), 5.10 (1H, t, *J*=3.6 Hz, H-12).

Lupeol acetate (3b): ¹H NMR (CDCl₃, 600 MHz): δ 4.67 (1H, brs, H-29b), 4.55 (1H, brs, H-29a), 4.45 (1H, dd, *J*=5, 13 Hz, H-3), 2.02 (3H, s, H-2 of OAc), 1.69 (3H, s, H-30), 1.05 (3H, s, H-25), 0.94 (3H, s, H-28), 0.86 (3H, s, H-23), 0.85 (3H, s, H-24), 0.83 (3H, s, H-26), 0.78 (3H, s, H-27).

β-Sitosterol (4a): ¹H NMR (600 MHz, CDCl₃): δ 3.51 (1H, m, H-3), 2.26, 2.21 (2H, H-4), 5.33 (1H, dd, *J*=5.4, 1.8 Hz, H-6), 0.66 (3H, s, H-18), 0.99 (3H, s, H-19), 0.90 (3H, d, *J*=6.6 Hz, H-21), 0.79 (3H, d, *J*=6.6 Hz, H-26), 0.82 (3H, d, *J*=7.2 Hz, H-27), 0.85 (3H, t, *J*=7.2 Hz, H-29).

Stigmasterol (4b): ¹H NMR (CDCl₃, 600 MHz): δ 0.68, 0.79, 0.82, 0.86, 0.91, 1.01 (each 3H, s, Me × 6), 3.51 (m, H-3), 5.33 (dd, *J*=5.4, 1.8 Hz, H-6), 5.14 (dd, *J*=9.0, 15.0 Hz, H-22), 5.01 (dd, *J*=9.0 Hz, 15.0 Hz, H-23).

Triacylglycerols (5): ¹³C NMR (150 MHz, CDCl₃): δ 62.09 (glyceryl CH₂), 68.86 (glyceryl CH), 173.30 (C=O β), 172.85, 172.84 (C=O α), 34.02, 34.05, 34.19 (C-2), 24.83, 24.86 (C-3), 27.17, 27.19, 27.22 (allylic CH₂), 25.62, 25.65, 29.05, 29.08, 29.12, 29.13, 29.17, 29.20, 29.27, 29.32, 29.34, 29.35, 29.36, 29.48, 29.52, 29.57, 29.62, 29.63, 29.66, 29.70, 29.76, 31.52, 31.90, 31.92 (CH₂)_n, 127.88–130.23 (127.88, 127.89, 128.06, 128.07, 129.68, 129.98, 130.01, 130.02, 130.23, CH=), 14.07, 14.12 (terminal CH₃).

Fatty alcohols (6): ¹H NMR (600 MHz, CDCl₃): δ 5.32 (t, *J*=4.8 Hz, =CH), 3.62 (t, *J*=6.6 Hz, terminal CH₂OH), 2.00 (allylic CH₂), 1.56 (m, α-CH₂), 1.23–1.34 (br s, CH₂), 0.86 (t, *J*=7.2 Hz, terminal CH₃).

RESULTS AND DISCUSSION

Silica gel chromatography of the dichloromethane extract of *Cycas vesperitilio* male cone afforded **1–6**. The structures of **1** and **2** were elucidated by extensive 1D and 2D NMR spectroscopy and confirmed by comparison of their ¹³C NMR data with those reported in the literature for **pinoresinol (1)**⁶ and **lariciresinol (2)**⁶. The structures of **3a–6** were identified by comparison of their NMR data with those reported in the literature for **α-amyrin acetate (3a)**⁷, **lupeol acetate (3b)**⁸, **β-sitosterol (4a)**⁹, **stigmasterol (4b)**⁸, **triglycerides (5)**¹⁰, and **fatty alcohols (6)**¹¹. The 2.5:1 ratio for the mixture of **3a** and **3b** was deduced from the ¹H NMR integrations for the olefinic protons at δ 5.10 for **3a** and δ 4.67 and 4.55 for **3b**. The 2:1 ratio for the mixture of **4a** and **4b** was deduced from the ¹H NMR integrations for the olefinic protons at δ 5.33 for **4a** and δ 5.33, 5.14 and 5.01 for **4b**.

Although no biological activity tests were conducted on the isolated compounds (**1–6**), a literature search of these compounds revealed that these have diverse bioactivities.

Pinoresinol (1) was found to have **antioxidant** and **Ca²⁺ antagonist properties**¹². It was reported to exhibit strong **antiinflammatory properties** by acting on the NF-κB signaling pathway¹³. Furthermore, **1** attenuates inflammatory responses of microglia and could be useful in modulation of inflammatory status in brain disorders¹⁴. Lignan **1** was shown to possess **fungicidal activities** and therapeutic potential as an antifungal agent for the treatment of fungal infectious diseases in humans¹⁵. It exhibited **inhibitory activity** against rat intestinal maltase with an IC₅₀ value of 34.3 μM¹⁶.

Lariciresinol (2) inhibited the **tumor growth and tumor angiogenesis**. In MCF-7 xenografts, **2** enhanced tumor cell apoptosis and increased estrogen receptor beta expression, indicating the importance of **2** in the inhibition of breast cancer development¹⁷. Furthermore, **2** inhibited lipid peroxidation and is a good scavenger of superoxide radicals¹⁸. Lignan **2** was also reported to possess **fungicidal activities** by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans¹⁹.

The oral administration of **α-amyrin acetate (3a)** significantly improved the diabetic condition in streptozotocin-induced diabetic rats and in model type 2 diabetic mice at 50 mg/kg⁻¹ dose level²⁰. Another study reported that **3a** showed **sedative, anxiolytic and anticonvulsant properties**²¹. On the other hand **lupeol acetate (3b)** was reported to exhibit a strong **antimicrobial effect** against gram positive organisms, but no activity against gram negative bacteria and fungi^{22,23}.

β-Sitosterol (4a) was observed to have growth inhibitory effects on human breast MCF-7 and MDA-MB-231 adenocarcinoma cells²⁴. It was shown to be effective for the treatment of benign prostatic hyperplasia²⁵. It was also reported to attenuate β-catenin and PCNA expression, as well as quench radical *in vitro*, making it a potential anticancer drug for colon carcinogenesis²⁶. It can inhibit the expression of NPC1L1 in the enterocytes to reduce intestinal cholesterol uptake²⁷. It was reported to induce apoptosis mediated by the activation of ERK and the

downregulation of Akt in MCA-102 murine fibrosarcoma cells²⁸. **Stigmasterol (4b)** shows **therapeutic efficacy** against Ehrlich ascites carcinoma bearing mice while conferring protection against cancer induced altered physiological conditions²⁹. It lowers plasma cholesterol levels, **inhibits intestinal cholesterol** and plant sterol absorption, and suppresses hepatic cholesterol and classic bile acid synthesis in Wistar as well as WKY rats³⁰. Other studies reported that **stigmasterol** showed **cytostatic activity** against Hep-2 and McCoy cells³¹, markedly inhibited tumour promotion in two stage carcinogenesis experiments³², exhibited **antimutagenic**³³, **topical anti-inflammatory**³⁴, **antiosteoarthritic**³⁵ and **antioxidant**³⁶ activities. **Triacylglycerides (5)** exhibited **antimicrobial activity** against *S. aureus*, *P. aeruginosa*, *B. subtilis*, *C. albicans*, and *T. mentagrophytes*³⁷. Another study reported that **triglycerides** showed a direct relationship between toxicity and increasing unsaturation, which in turn correlated with increasing susceptibility to oxidation³⁸. On the other hand, **long-chain fatty alcohols (6)** was reported to exhibit a protective effect on some mediators involved in the inflammatory damage development³⁹.

CONCLUSION

The dichloromethane extracts of *Cycas vespertilio*, a plant endemic to the Philippines, afforded **pinoresinol (1)**, **lariciresinol (2)**, **α -amyrin acetate (3a)**, **lupeol acetate (3b)**, **β -sitosterol (4a)**, **stigmasterol (4b)**, **triglycerides (5)**, and **fatty alcohols (6)**. Compounds **1-6** were reported to exhibit diverse biological activities.

ACKNOWLEDGEMENT

A research grant from the Commission on Higher Education –Philippine Higher Education Research Network (CHED–PHERNet) of the Philippines is gratefully acknowledged.

REFERENCES

- Nagalingum NS, Marshal CR, Quental TB, Tai HS, Little DP, Matthews S. Recent synchronous radiation of a living fossil. Science 2011; 334(6057):796.
- Donaldson JS. Cycads. Status survey and conservation action plan. IUCN Gland, Switzerland and Cambridge, U.K.; 2003.
- Madulid DA, Agoo EMG. Taxonomy and conservation of Philippine cycads. Blumea 2009; 54:99.
- Lindstrom AJ, Hill KD, Stanberg LC. The genus *Cycas* (Cycadaceae) in the Philippines. Telopea 2008; 12:119–145.
- Ng VAS, Agoo EM, Shen C-C, Ragasa CY. Chemical constituents of *Cycas sancti-lasallei*. J Appl Pharm Sci 2015; 5(Suppl 1):12-17.
- Ragasa CY, Hofileña JG, Rideout JA. Lignans from *Gliricidia sepium*. ACGC Chem Res Commun 2000; 10:52-60.
- Feleke S, Brehane A. Triterpene compounds from the latex of *Ficus sur* I. Bull Chem Soc Ethiop 2005; 19(2):307-310.
- Jamal AK, Yaacob WA, Din LB. A chemical study on *Phyllanthus reticulatus*. J Phys Sci 2008; 19(2):45–50.
- Ragasa CY, Ng VAS, De Los Reyes MM, Mandia EH, Oyong GG, Shen C-C. Chemical constituents and cytotoxicity of the leaves of *Dysoxylum gaudichaudianum* (A. Juss.) Miq. Der Pharma Chemica. 2014; 6(5):182-187.
- Ng VAS, Agoo EM, Shen C-C, Ragasa CY. Chemical constituents of *Cycas sancti-lasallei*. J Appl Pharm Sci 2015; 5(Suppl 1):12-17.
- Ragasa CY, Torres OB, Mandia EH, Shen C-C. Chemical constituents of *Terminalia microcarpa*. Der Pharmacia Lettre 2014; 6(6):439-442.
- Páska C, Innocenti G, Ferlin M, Kunvári M, László M. Pinoresinol from *Ipomoea cairica* cell cultures. Nat Prod Lett 2002; 16(5):359-63.
- During A, Debouche C, Raas T, Larondelle Y. Among plant lignans, pinoresinol has the strongest antiinflammatory properties in human intestinal Caco-2 cells. J Nutr 2012; 142(10):1798-1805.
- Jung HW, Mahesh R, Lee JG, Lee SH, Kim YS, Park Y-K. Pinoresinol from the fruits of *Forsythia koreana* inhibits inflammatory responses in LPS-activated microglia. Neurosci Lett 2010; 480(3):215-220.
- Hwang B, Lee J, Liu Q-H, Woo E-R, Lee DG. Antifungal effect of (+)-pinoresinol isolated from *Sambucus williamsii*. Molecules 2010; 15(5):3507-3516.
- Wikul A, Damsud T, Kataoka K, Phuwapraisirisan P. (+)-Pinoresinol is a putative hypoglycemic agent in defatted sesame (*Sesamum indicum*) seeds though inhibiting α -glucosidase. Bioorg Med Chem Lett 2012; 22(16):5215-5217.
- Saarinen NM, Wärrä A, Dings RPM, Airio M, Smeds AI, Mäkelä S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer 2008; 123(5):1196-1204.
- Redzynia I, Ziolkowska NE, Majzner WR, Willfor S, Sjöholm R, Eklund P, Bujacz GD. Structural investigation of biologically active phenolic compounds isolated from European tree species. Molecules 2009; 14(10):4147-4158.
- Hwang B, Cho J, Hwang I-S, Jin H-G, Woo E-R, Lee DG. Antifungal activity of lariciresinol derived from *Sambucus williamsii* and their membrane-active mechanisms in *Candida albicans*. Biochem Biophys Res Commun 2011; 410(3):489-93.
- Singh AB, Yadav DK, Maurya R, Srivastava AK. Antihyperglycaemic activity of α -amyrin acetate in rats and db/db mice. Nat Prod Res 2009; 23(9):876-882.
- Aragao GF, Carneiro LMV, Junior APF, Bandeira PN, Lemos TLG, Viana GSdeB. Evidence for excitatory and inhibitory amino acids participation in the neuropharmacological activity of α - and β -amyrinacetate. Open Pharmacol J 2009; 3:9-16.
- Freire MdeF, Geraldo de Carvalho M, Berbara RLL, Freire RB. Antimicrobial activity of lupeolacetate from

- Vernonia scorpioides* (Lam.) Pers., Asteraceae. Revista Brasileira de Farmacia (2002), 83(1/4), 83-87.
23. Abdel-Rahman Tahany MA, Hegazy AK, Mohsen Sayed A, Kabiell HF, El-Alfy T, El-Komy SM. Study on combined antimicrobial activity of some biologically active constituents from wild *Moringa peregrina* Forssk. J Yeast Fungal Res 2010; 1(1):15-24.
24. Awad AB, Chinnman M, Fink CS, Bradford PG. β -Sitosterol activates Fas signaling in human breast cancer cells. Phytomed 2007; 14:747-754.
25. Jayaprakasha GK, Mandadi KK, Poulouse SM, Jadegoud Y, Gowda GA, Patil BS. Inhibition of colon cancer growth and antioxidant activity of bioactive compounds from *Poncirus trifoliata* (L.) Raf. Bioorg Med Chem 2007; 15:4923-4932.
26. Baskar AA, Ignacimuthu S, Paulraj G, Numair K. Chemopreventive potential of β -sitosterol in experimental colon cancer model - an *in vitro* and *in vivo* study. BMC Comp Alt Med 2010; 10:24.
27. Jesch ED, Seo JM, Carr TP, Lee JY. Sitosterol reduces messenger RNA and protein expression levels of Niemann-Pick C1-like 1 in FHs 74 Int cells. Nutr Res 2009; 29(12):859-66.
28. Moon DO, Lee KJ, Choi YH, Kim GY. β -Sitosterol-induced-apoptosis is mediated by the activation of ERK and the downregulation of Akt in MCA-102 murine fibrosarcoma cells. Int Immunopharmacol 2007; 7:1044-1053.
29. Ghosh T, Maity TK, Singh J. Evaluation of antitumor activity of stigmasterol, a constituent isolated from *Bacopa monnieri* Linn aerial parts against ehrlich ascites carcinoma in mice. Orient Pharm Exp Med 2011; 11:41-49.
30. Batta AK, Xu G, Honda A, Miyazaki T, Salen G. Stigmasterol reduces plasma cholesterol levels and inhibits hepatic synthesis and intestinal absorption in the rat. Metabolism 2006; 55(3):292-299.
31. Gómez MA, García MD, Sáenz MT. Cytostatic activity of *Achillea ageratum* L. Phytother Res 2001; 15(7):633-634.
32. Kasahara Y, Kumaki K, Katagiri S, Yasukawa K, Yamanouchi S, Takido M. Carthami flos extract and its component, stigmasterol, inhibit tumour promotion in mouse skin two-stage carcinogenesis. Phytother Res 1994; 8(6):327-331.
33. Lim J-C, Park JH, Budesinsky M, Kasal A, Han Y-H, Koo B-S, Lee S-I, Lee D-U. Antimutagenic constituents from the thorns of *Gleditsia sinensis*. Chem Pharm Bull 2005; 53(5):561-564.
34. García MD, Sáenz MT, Gómez MA, Fernández MA. Topical anti-inflammatory activity of phytosterols isolated from *Eryngium foetidum* chronic and acute inflammation models. Phytother Res 1999; 13(1):78-80.
35. Gabay O, Sanchez C, Salvat C, Chevy F, Breton M, Nourissat G. Stigmasterol: a phytosterol with potential anti-osteoarthritic properties. Osteoarthritis Cartilage 2010; 18(1):106-116.
36. Panda S, Jafri M, Kar A, Meheta BK. Thyroid inhibitory, antiperoxidative and hypoglycemic effects of stigmasterol, isolated from *Butea monosperma*. Fitoter 2009; 80(2):123-126.
37. Ragasa CY, Lorena GS, Mandia EH, Raga DD, Shen C-C. Chemical constituents of *Abrus precatorius*. Amer J Essent Oils Nat Prod 2013; 1(2):7-10.
38. Ferruzzi MG, Blakeslee J. Digestion, absorption, and cancer preventative activity of dietary chlorophyll derivatives. Nutr Res 2007; 27:1-12.
39. Fernandez-Arche A, Marquez-Martin A, De La Puerta Vazquez R, Perona JS, Terencio C, Perez-Camino C, Ruiz-Gutierrez V. Long-chain fatty alcohols from pomace olive oil modulate the release of pro-inflammatory mediators. Downloaded from digital.csic.es/bitstream/10261/55289/3/Pro-inflammatory.pdf on May 20, 2015.